Nizozemsko - nizozemština - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

cheplapharm arzneimittel gmbh ziegelhof 24 17489 greifswald (duitsland) - etoposide 50 mg/stuk - capsule, zacht - citroenzuur 0-water (e 330) ; gelatine (e 441) ; glycerol 85 per cent (e 422) ; ijzeroxide rood (e 172) ; macrogol 400 ; natriumethylparahydroxybenzoaat (e 215) ; natriumpropylparahydroxybenzoaat ; titaandioxide (e 171) ; water, gezuiverd, citroenzuur 0-water (e 330) ; gelatine (e 441) ; glycerol 85 per cent (e 422) ; ijzeroxide rood (e 172) ; macrogol 400 ; natriumethylparahydroxybenzoaat ; natriumpropylparahydroxybenzoaat ; titaandioxide (e 171) ; water, gezuiverd, citroenzuur 0-water (e 330) ; gelatine (e 441) ; glycerol 85 per cent (e 422) ; ijzeroxide rood (e 172) ; macrogol 400 ; natriumethylparahydroxybenzoaat ; natriumpropylparahydroxybenzoaat (e 217) ; titaandioxide (e 171) ; water, gezuiverd, - etoposide

Nizozemsko - nizozemština - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

eureco-pharma b.v. boelewerf 2 2987 vd ridderkerk - etoposide 100 mg/stuk - capsule, zacht - citroenzuur 0-water (e 330) ; gelatine (e 441) ; glycerol 85 per cent (e 422) ; ijzeroxide rood (e 172) ; macrogol 400 ; natriummethylparahydroxybenzoaat (e 219) ; natriumpropylparahydroxybenzoaat ; titaandioxide (e 171) ; water, gezuiverd, citroenzuur 0-water (e 330) ; gelatine (e 441) ; glycerol 85 per cent (e 422) ; ijzeroxide rood (e 172) ; macrogol 400 ; natriummethylparahydroxybenzoaat (e 219) ; natriumpropylparahydroxybenzoaat (e 217) ; titaandioxide (e 171) ; water, gezuiverd

Nizozemsko - nizozemština - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

etoposide - capsule, zacht - citroenzuur 0-water (e 330) ; gelatine (e 441) ; glycerol 85 per cent (e 422) ; ijzeroxide rood (e 172) ; macrogol 400 ; natriummethylparahydroxybenzoaat (e 219) ; natriumpropylparahydroxybenzoaat (e 217) ; titaandioxide (e 171) ; water, gezuiverd

Nizozemsko - nizozemština - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

eureco-pharma b.v. boelewerf 2 2987 vd ridderkerk - etoposide 100 mg/stuk - capsule, zacht - citroenzuur 0-water (e 330) ; gelatine (e 441) ; glycerol 85 per cent (e 422) ; ijzeroxide rood (e 172) ; macrogol 400 ; natriummethylparahydroxybenzoaat (e 219) ; natriumpropylparahydroxybenzoaat ; titaandioxide (e 171) ; water, gezuiverd, citroenzuur 0-water (e 330) ; gelatine (e 441) ; glycerol 85 per cent (e 422) ; ijzeroxide rood (e 172) ; macrogol 400 ; natriummethylparahydroxybenzoaat (e 219) ; natriumpropylparahydroxybenzoaat (e 217) ; titaandioxide (e 171) ; water, gezuiverd

Nizozemsko - nizozemština - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

eureco-pharma b.v. boelewerf 2 2987 vd ridderkerk - etoposide 50 mg/stuk - capsule, zacht - citroenzuur 0-water (e 330) ; gelatine (e 441) ; glycerol 85 per cent (e 422) ; ijzeroxide rood (e 172) ; macrogol 400 ; natriummethylparahydroxybenzoaat (e 219) ; natriumpropylparahydroxybenzoaat ; titaandioxide (e 171) ; water, gezuiverd, citroenzuur 0-water (e 330) ; gelatine (e 441) ; glycerol 85 per cent (e 422) ; ijzeroxide rood (e 172) ; macrogol 400 ; natriummethylparahydroxybenzoaat (e 219) ; natriumpropylparahydroxybenzoaat (e 217) ; titaandioxide (e 171) ; water, gezuiverd

Nizozemsko - nizozemština - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

etoposide 100 mg/stuk - capsule, zacht - citroenzuur 0-water (e 330) ; gelatine (e 441) ; glycerol 85 per cent (e 422) ; ijzeroxide rood (e 172) ; macrogol 400 ; natriumethylparahydroxybenzoaat (e 215) ; natriumpropylparahydroxybenzoaat ; titaandioxide (e 171) ; water, gezuiverd, citroenzuur 0-water (e 330) ; gelatine (e 441) ; glycerol 85 per cent (e 422) ; ijzeroxide rood (e 172) ; macrogol 400 ; natriumethylparahydroxybenzoaat ; natriumpropylparahydroxybenzoaat ; titaandioxide (e 171) ; water, gezuiverd, citroenzuur 0-water (e 330) ; gelatine (e 441) ; glycerol 85 per cent (e 422) ; ijzeroxide rood (e 172) ; macrogol 400 ; natriumethylparahydroxybenzoaat ; natriumpropylparahydroxybenzoaat (e 217) ; titaandioxide (e 171) ; water, gezuiverd

Nizozemsko - nizozemština - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

etoposide 50 mg/stuk - capsule, zacht - citroenzuur 0-water (e 330) ; gelatine (e 441) ; glycerol 85 per cent (e 422) ; ijzeroxide rood (e 172) ; macrogol 400 ; natriumethylparahydroxybenzoaat (e 215) ; natriumpropylparahydroxybenzoaat ; titaandioxide (e 171) ; water, gezuiverd, citroenzuur 0-water (e 330) ; gelatine (e 441) ; glycerol 85 per cent (e 422) ; ijzeroxide rood (e 172) ; macrogol 400 ; natriumethylparahydroxybenzoaat ; natriumpropylparahydroxybenzoaat ; titaandioxide (e 171) ; water, gezuiverd, citroenzuur 0-water (e 330) ; gelatine (e 441) ; glycerol 85 per cent (e 422) ; ijzeroxide rood (e 172) ; macrogol 400 ; natriumethylparahydroxybenzoaat ; natriumpropylparahydroxybenzoaat (e 217) ; titaandioxide (e 171) ; water, gezuiverd

Evropská unie - nizozemština - EMA (European Medicines Agency)

roche registration gmbh - atezolizumab - carcinoma, transitional cell; carcinoma, non-small-cell lung; urologic neoplasms; breast neoplasms; small cell lung carcinoma - antineoplastische middelen - urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or - who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancer tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non small cell lung cancer (nsclc). in patients with egfr mutant or alk-positive nsclc, tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies (see section 5. tecentriq, in combination with nab paclitaxel and carboplatin, is indicated for the first line treatment of adult patients with metastatic non-squamous nsclc who do not have egfr mutant or alk positive nsclc (see section 5. tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq als monotherapie is geïndiceerd voor de behandeling van volwassen patiënten met lokaal gevorderd of gemetastaseerd niet-kleincellig longcarcinoom na voorafgaande chemotherapie. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. small cell lung cancertecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (es-sclc) (see section 5. hepatocellular carcinomatecentriq, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (hcc) who have not received prior systemic therapy (see section 5. urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or- who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancertecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq als monotherapie is geïndiceerd voor de behandeling van volwassen patiënten met lokaal gevorderd of gemetastaseerd niet-kleincellig longcarcinoom na voorafgaande chemotherapie. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. triple-negative breast cancertecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (tnbc) whose tumours have pd-l1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.

Nizozemsko - nizozemština - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

glaxosmithkline b.v. van asch van wijckstraat 55h 3811 lp amersfoort - atovaquon 250 mg/stuk ; proguanilhydrochloride 100 mg/stuk samenstelling overeenkomend met ; proguanil 87,4 mg/stuk - filmomhulde tablet - cellulose, microkristallijn (e 460(i)) ; hydroxypropylcellulose, laag gesubstitueerd (e 463a) ; hypromellose (e 464) ; ijzeroxide rood (e 172) ; macrogol 400 ; macrogol 8000 ; magnesiumstearaat (e 470b) ; natriumzetmeelglycolaat ; poloxameer 188 ; povidon k 30 (e 1201) ; titaandioxide (e 171), cellulose, microkristallijn (e 460) ; hydroxypropylcellulose, laag gesubstitueerd (e 463) ; hypromellose (e 464) ; ijzeroxide rood (e 172) ; macrogol 400 ; macrogol 8000 ; magnesiumstearaat (e 470b) ; natriumzetmeelglycolaat ; poloxameer 188 ; povidon k 30 (e 1201) ; titaandioxide (e 171), cellulose, microkristallijn (e 460) ; hydroxypropylcellulose, laag gesubstitueerd (e 463) ; hypromellose (e 464) ; ijzeroxide rood (e 172) ; macrogol 400 ; macrogol 8000 ; magnesiumstearaat (e 470b) ; natriumzetmeelglycolaat (e468) ; poloxameer 188 ; povidon k 30 (e 1201) ; titaandioxide (e 171), - proguanil, combinations

Nizozemsko - nizozemština - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

euro registratie collectief b.v. van der giessenweg 5 2921 lp krimpen a/d ijssel - atovaquon ; proguanilhydrochloride samenstelling overeenkomend met ; proguanil - filmomhulde tablet - cellulose, microkristallijn (e 460) ; hydroxypropylcellulose, laag gesubstitueerd (e 463) ; hypromellose (e 464) ; ijzeroxide rood (e 172) ; macrogol 400 ; macrogol 8000 ; magnesiumstearaat (e 470b) ; natriumzetmeelglycolaat ; poloxameer 188 ; povidon k 30 (e 1201) ; titaandioxide (e 171), cellulose, microkristallijn (e 460) ; hydroxypropylcellulose, laag gesubstitueerd (e 463) ; hypromellose (e 464) ; ijzeroxide rood (e 172) ; macrogol 400 ; macrogol 8000 ; magnesiumstearaat (e 470b) ; natriumzetmeelglycolaat (e468) ; poloxameer 188 ; povidon k 30 (e 1201) ; titaandioxide (e 171), - proguanil, combinations